Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.
Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
LBA vs. Intact LC/HRAM for ADC Quantification: What Each Method Actually Measures
Selecting a bioanalytical platform for antibody-drug conjugates is a structural decision: deconjugation and DAR shift mean the circulating analyte changes continuously after dosing. Two 2026 publications, an AAPS ADC Working Group white paper and a peer-reviewed PPD hybrid assay validation, sharpen the practical framework for LBA, intact LC/HRAM, and hybrid LBA-LC-MS approaches in regulated ADC studies.
Immunogenicity Assessment for LNP-Based Therapeutics: Mapping the Assay Demands Across Innate and Adaptive Endpoints
LNP-based therapeutics generate immunogenicity signals across at least two immune layers, involving carrier and cargo independently, against a background of pre-existing anti-PEG antibodies in a substantial fraction of patients. No finalized LNP-specific immunogenicity guidance exists, leaving bioanalytical scientists to build assay strategies from the LNP-specific evidence base up. This article maps the cytokine, complement, anti-PEG, and cellular endpoints that a fit-for-purpose panel must address.
Four Analytes, One Plasma Sample: The Assay Science Behind Multi-Biomarker Alzheimer's Testing
Four blood-based Alzheimer's disease biomarker tests were cleared by the FDA within fifteen months, and a five-analyte algorithmic panel is under 510(k) review. For immunoassay scientists deploying these panels, the analytical challenges of femtomolar sensitivity, cross-reactivity between tau isoforms, preanalytical instability of Aβ42, and cross-platform harmonization are the least-settled problems in making multi-biomarker results hold up outside a research cohort.